Sevoflurane-induced cardioprotection in coronary artery bypass graft surgery: Randomised trial with clinical and ex-vivo endpoints
Myocardial ischaemia reperfusion injury following cardiac surgery with cardiopulmonary bypass (CPB) increases postoperative mortality. Setting techniques to protect the heart during this critical period therefore represents a considerable challenge. A randomised controlled study in Caen University H...
Gespeichert in:
| Veröffentlicht in: | Anaesthesia critical care & pain medicine 2018-06, Vol.37 (3), p.217-223 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 223 |
|---|---|
| container_issue | 3 |
| container_start_page | 217 |
| container_title | Anaesthesia critical care & pain medicine |
| container_volume | 37 |
| creator | Lemoine, Sandrine Zhu, Lan Gérard, Jean-Louis Hanouz, Jean-Luc |
| description | Myocardial ischaemia reperfusion injury following cardiac surgery with cardiopulmonary bypass (CPB) increases postoperative mortality. Setting techniques to protect the heart during this critical period therefore represents a considerable challenge.
A randomised controlled study in Caen University Hospital Centre, investigated whether the clinical cardio protective effects of administration sevoflurane before cardiopulmonary bypass during coronary artery bypass graft surgery (CABG) could translate into protected atrial trabeculae contractility against hypoxia–reoxygenation in vitro. Patients undergoing elective on-pump CABG surgery were allocated to receive either sevoflurane (n=24) or no halogenated volatile anaesthetic (n=21). Main outcome measures: the relationship between sevoflurane exposure before CPB and the incidence of major adverse cardiac events, with primary endpoint: the postoperative troponin I peak level, and secondary endpoints: the inotropic support, and the duration of stay in intensive unit and in-hospital stay were chosen as study endpoints. The right atrial was collected at the beginning of bypass surgery for the in vitro experimentation. Isometrically contracting isolated human right atrial trabeculae obtained from the two groups were exposed to 30-min hypoxia followed by 60-min reoxygenation.
The patients receiving sevoflurane prior to aortic clamping significantly exhibited less cardiac Troponin I (1.39 [0.34–2.97] vs. 2.80 [2.54–3.64] ng·mL−1 in Control; P=0.03) and required a reduced inotropic drug support (P |
| doi_str_mv | 10.1016/j.accpm.2017.05.009 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1935813333</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2352556817300267</els_id><sourcerecordid>1935813333</sourcerecordid><originalsourceid>FETCH-LOGICAL-c359t-cf8ab5f9a4addc016306cd692a6d68ee45e2d45be03b0d3551a1d2d6b90a0b9e3</originalsourceid><addsrcrecordid>eNp9kMFO3DAQhq2KqqCFJ6hU-cglYRzH2aQSB4QoVFqpEoWz5dgT6lXWTm1nKVeeHG-XIk71ZeyZf2b8f4R8ZlAyYM3ZulRaT5uyArYsQZQA3QdyVHFRFUI07cG7-yE5iXENAKxulrxbfiKHVdsuoa3bI_L8E7d-GOegHBbWmVmjoVoFY_0UfEKdrHfUOqp98E6FJ6pCwhz6p0nFSB-CGhKNc3jIya_0VjnjNzbmISlYNdJHm35RPVpndX7lKsU_xdZuPUVnJm9disfk46DGiCevcUHuv13dXd4Uqx_X3y8vVoXmokuFHlrVi6FTtTJGZwYcGm2arlKNaVrEWmBlatEj8B4MF4IpZirT9B0o6DvkC3K6n5uN_Z4xJpk_qnEcs3U_R8k6LlrGd2dB-F6qg48x4CCnYDfZvWQgd_zlWv7lL3f8JQiZ-eeuL68L5n6D5q3nH-0sON8LMNvcWgwyaosuI7chk5bG2_8ueAHxjJts</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1935813333</pqid></control><display><type>article</type><title>Sevoflurane-induced cardioprotection in coronary artery bypass graft surgery: Randomised trial with clinical and ex-vivo endpoints</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Lemoine, Sandrine ; Zhu, Lan ; Gérard, Jean-Louis ; Hanouz, Jean-Luc</creator><creatorcontrib>Lemoine, Sandrine ; Zhu, Lan ; Gérard, Jean-Louis ; Hanouz, Jean-Luc</creatorcontrib><description>Myocardial ischaemia reperfusion injury following cardiac surgery with cardiopulmonary bypass (CPB) increases postoperative mortality. Setting techniques to protect the heart during this critical period therefore represents a considerable challenge.
A randomised controlled study in Caen University Hospital Centre, investigated whether the clinical cardio protective effects of administration sevoflurane before cardiopulmonary bypass during coronary artery bypass graft surgery (CABG) could translate into protected atrial trabeculae contractility against hypoxia–reoxygenation in vitro. Patients undergoing elective on-pump CABG surgery were allocated to receive either sevoflurane (n=24) or no halogenated volatile anaesthetic (n=21). Main outcome measures: the relationship between sevoflurane exposure before CPB and the incidence of major adverse cardiac events, with primary endpoint: the postoperative troponin I peak level, and secondary endpoints: the inotropic support, and the duration of stay in intensive unit and in-hospital stay were chosen as study endpoints. The right atrial was collected at the beginning of bypass surgery for the in vitro experimentation. Isometrically contracting isolated human right atrial trabeculae obtained from the two groups were exposed to 30-min hypoxia followed by 60-min reoxygenation.
The patients receiving sevoflurane prior to aortic clamping significantly exhibited less cardiac Troponin I (1.39 [0.34–2.97] vs. 2.80 [2.54–3.64] ng·mL−1 in Control; P=0.03) and required a reduced inotropic drug support (P<0.001). Isolated trabeculae from patients receiving sevoflurane enhanced the recovery of force after reoxygenation compared to the Control group (79±5% vs. 53±8% of baseline in Control; P<0.001).
Administration of sevoflurane before CPB induced cardioprotection in patients undergoing CABG and preconditioned human myocardium against hypoxia-reoxygenation in vitro.</description><identifier>ISSN: 2352-5568</identifier><identifier>EISSN: 2352-5568</identifier><identifier>DOI: 10.1016/j.accpm.2017.05.009</identifier><identifier>PMID: 28870848</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>Aged ; Aged, 80 and over ; Anesthetics, Inhalation ; Cardiac surgery ; Cardiotonic Agents ; Coronary Artery Bypass - methods ; Female ; Heart Diseases - epidemiology ; Heart Diseases - prevention & control ; Humans ; Hypoxia - etiology ; Incidence ; Inotropic drug support ; Intraoperative Complications - epidemiology ; Intraoperative Complications - prevention & control ; Isolated trabeculae contractility ; Male ; Middle Aged ; Myocardial Contraction - drug effects ; Postoperative Complications - epidemiology ; Postoperative Complications - prevention & control ; Preconditioning ; Sevoflurane ; Treatment Outcome ; Troponin ; Troponin I - analysis</subject><ispartof>Anaesthesia critical care & pain medicine, 2018-06, Vol.37 (3), p.217-223</ispartof><rights>2017 Société française d'anesthésie et de réanimation (Sfar)</rights><rights>Copyright © 2018 Société française d'anesthésie et de réanimation (Sfar). Published by Elsevier Masson SAS. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c359t-cf8ab5f9a4addc016306cd692a6d68ee45e2d45be03b0d3551a1d2d6b90a0b9e3</citedby><cites>FETCH-LOGICAL-c359t-cf8ab5f9a4addc016306cd692a6d68ee45e2d45be03b0d3551a1d2d6b90a0b9e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27911,27912</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28870848$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lemoine, Sandrine</creatorcontrib><creatorcontrib>Zhu, Lan</creatorcontrib><creatorcontrib>Gérard, Jean-Louis</creatorcontrib><creatorcontrib>Hanouz, Jean-Luc</creatorcontrib><title>Sevoflurane-induced cardioprotection in coronary artery bypass graft surgery: Randomised trial with clinical and ex-vivo endpoints</title><title>Anaesthesia critical care & pain medicine</title><addtitle>Anaesth Crit Care Pain Med</addtitle><description>Myocardial ischaemia reperfusion injury following cardiac surgery with cardiopulmonary bypass (CPB) increases postoperative mortality. Setting techniques to protect the heart during this critical period therefore represents a considerable challenge.
A randomised controlled study in Caen University Hospital Centre, investigated whether the clinical cardio protective effects of administration sevoflurane before cardiopulmonary bypass during coronary artery bypass graft surgery (CABG) could translate into protected atrial trabeculae contractility against hypoxia–reoxygenation in vitro. Patients undergoing elective on-pump CABG surgery were allocated to receive either sevoflurane (n=24) or no halogenated volatile anaesthetic (n=21). Main outcome measures: the relationship between sevoflurane exposure before CPB and the incidence of major adverse cardiac events, with primary endpoint: the postoperative troponin I peak level, and secondary endpoints: the inotropic support, and the duration of stay in intensive unit and in-hospital stay were chosen as study endpoints. The right atrial was collected at the beginning of bypass surgery for the in vitro experimentation. Isometrically contracting isolated human right atrial trabeculae obtained from the two groups were exposed to 30-min hypoxia followed by 60-min reoxygenation.
The patients receiving sevoflurane prior to aortic clamping significantly exhibited less cardiac Troponin I (1.39 [0.34–2.97] vs. 2.80 [2.54–3.64] ng·mL−1 in Control; P=0.03) and required a reduced inotropic drug support (P<0.001). Isolated trabeculae from patients receiving sevoflurane enhanced the recovery of force after reoxygenation compared to the Control group (79±5% vs. 53±8% of baseline in Control; P<0.001).
Administration of sevoflurane before CPB induced cardioprotection in patients undergoing CABG and preconditioned human myocardium against hypoxia-reoxygenation in vitro.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anesthetics, Inhalation</subject><subject>Cardiac surgery</subject><subject>Cardiotonic Agents</subject><subject>Coronary Artery Bypass - methods</subject><subject>Female</subject><subject>Heart Diseases - epidemiology</subject><subject>Heart Diseases - prevention & control</subject><subject>Humans</subject><subject>Hypoxia - etiology</subject><subject>Incidence</subject><subject>Inotropic drug support</subject><subject>Intraoperative Complications - epidemiology</subject><subject>Intraoperative Complications - prevention & control</subject><subject>Isolated trabeculae contractility</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Myocardial Contraction - drug effects</subject><subject>Postoperative Complications - epidemiology</subject><subject>Postoperative Complications - prevention & control</subject><subject>Preconditioning</subject><subject>Sevoflurane</subject><subject>Treatment Outcome</subject><subject>Troponin</subject><subject>Troponin I - analysis</subject><issn>2352-5568</issn><issn>2352-5568</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMFO3DAQhq2KqqCFJ6hU-cglYRzH2aQSB4QoVFqpEoWz5dgT6lXWTm1nKVeeHG-XIk71ZeyZf2b8f4R8ZlAyYM3ZulRaT5uyArYsQZQA3QdyVHFRFUI07cG7-yE5iXENAKxulrxbfiKHVdsuoa3bI_L8E7d-GOegHBbWmVmjoVoFY_0UfEKdrHfUOqp98E6FJ6pCwhz6p0nFSB-CGhKNc3jIya_0VjnjNzbmISlYNdJHm35RPVpndX7lKsU_xdZuPUVnJm9disfk46DGiCevcUHuv13dXd4Uqx_X3y8vVoXmokuFHlrVi6FTtTJGZwYcGm2arlKNaVrEWmBlatEj8B4MF4IpZirT9B0o6DvkC3K6n5uN_Z4xJpk_qnEcs3U_R8k6LlrGd2dB-F6qg48x4CCnYDfZvWQgd_zlWv7lL3f8JQiZ-eeuL68L5n6D5q3nH-0sON8LMNvcWgwyaosuI7chk5bG2_8ueAHxjJts</recordid><startdate>201806</startdate><enddate>201806</enddate><creator>Lemoine, Sandrine</creator><creator>Zhu, Lan</creator><creator>Gérard, Jean-Louis</creator><creator>Hanouz, Jean-Luc</creator><general>Elsevier Masson SAS</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201806</creationdate><title>Sevoflurane-induced cardioprotection in coronary artery bypass graft surgery: Randomised trial with clinical and ex-vivo endpoints</title><author>Lemoine, Sandrine ; Zhu, Lan ; Gérard, Jean-Louis ; Hanouz, Jean-Luc</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c359t-cf8ab5f9a4addc016306cd692a6d68ee45e2d45be03b0d3551a1d2d6b90a0b9e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anesthetics, Inhalation</topic><topic>Cardiac surgery</topic><topic>Cardiotonic Agents</topic><topic>Coronary Artery Bypass - methods</topic><topic>Female</topic><topic>Heart Diseases - epidemiology</topic><topic>Heart Diseases - prevention & control</topic><topic>Humans</topic><topic>Hypoxia - etiology</topic><topic>Incidence</topic><topic>Inotropic drug support</topic><topic>Intraoperative Complications - epidemiology</topic><topic>Intraoperative Complications - prevention & control</topic><topic>Isolated trabeculae contractility</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Myocardial Contraction - drug effects</topic><topic>Postoperative Complications - epidemiology</topic><topic>Postoperative Complications - prevention & control</topic><topic>Preconditioning</topic><topic>Sevoflurane</topic><topic>Treatment Outcome</topic><topic>Troponin</topic><topic>Troponin I - analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lemoine, Sandrine</creatorcontrib><creatorcontrib>Zhu, Lan</creatorcontrib><creatorcontrib>Gérard, Jean-Louis</creatorcontrib><creatorcontrib>Hanouz, Jean-Luc</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Anaesthesia critical care & pain medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lemoine, Sandrine</au><au>Zhu, Lan</au><au>Gérard, Jean-Louis</au><au>Hanouz, Jean-Luc</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sevoflurane-induced cardioprotection in coronary artery bypass graft surgery: Randomised trial with clinical and ex-vivo endpoints</atitle><jtitle>Anaesthesia critical care & pain medicine</jtitle><addtitle>Anaesth Crit Care Pain Med</addtitle><date>2018-06</date><risdate>2018</risdate><volume>37</volume><issue>3</issue><spage>217</spage><epage>223</epage><pages>217-223</pages><issn>2352-5568</issn><eissn>2352-5568</eissn><abstract>Myocardial ischaemia reperfusion injury following cardiac surgery with cardiopulmonary bypass (CPB) increases postoperative mortality. Setting techniques to protect the heart during this critical period therefore represents a considerable challenge.
A randomised controlled study in Caen University Hospital Centre, investigated whether the clinical cardio protective effects of administration sevoflurane before cardiopulmonary bypass during coronary artery bypass graft surgery (CABG) could translate into protected atrial trabeculae contractility against hypoxia–reoxygenation in vitro. Patients undergoing elective on-pump CABG surgery were allocated to receive either sevoflurane (n=24) or no halogenated volatile anaesthetic (n=21). Main outcome measures: the relationship between sevoflurane exposure before CPB and the incidence of major adverse cardiac events, with primary endpoint: the postoperative troponin I peak level, and secondary endpoints: the inotropic support, and the duration of stay in intensive unit and in-hospital stay were chosen as study endpoints. The right atrial was collected at the beginning of bypass surgery for the in vitro experimentation. Isometrically contracting isolated human right atrial trabeculae obtained from the two groups were exposed to 30-min hypoxia followed by 60-min reoxygenation.
The patients receiving sevoflurane prior to aortic clamping significantly exhibited less cardiac Troponin I (1.39 [0.34–2.97] vs. 2.80 [2.54–3.64] ng·mL−1 in Control; P=0.03) and required a reduced inotropic drug support (P<0.001). Isolated trabeculae from patients receiving sevoflurane enhanced the recovery of force after reoxygenation compared to the Control group (79±5% vs. 53±8% of baseline in Control; P<0.001).
Administration of sevoflurane before CPB induced cardioprotection in patients undergoing CABG and preconditioned human myocardium against hypoxia-reoxygenation in vitro.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>28870848</pmid><doi>10.1016/j.accpm.2017.05.009</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2352-5568 |
| ispartof | Anaesthesia critical care & pain medicine, 2018-06, Vol.37 (3), p.217-223 |
| issn | 2352-5568 2352-5568 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1935813333 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Aged Aged, 80 and over Anesthetics, Inhalation Cardiac surgery Cardiotonic Agents Coronary Artery Bypass - methods Female Heart Diseases - epidemiology Heart Diseases - prevention & control Humans Hypoxia - etiology Incidence Inotropic drug support Intraoperative Complications - epidemiology Intraoperative Complications - prevention & control Isolated trabeculae contractility Male Middle Aged Myocardial Contraction - drug effects Postoperative Complications - epidemiology Postoperative Complications - prevention & control Preconditioning Sevoflurane Treatment Outcome Troponin Troponin I - analysis |
| title | Sevoflurane-induced cardioprotection in coronary artery bypass graft surgery: Randomised trial with clinical and ex-vivo endpoints |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T11%3A29%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sevoflurane-induced%20cardioprotection%20in%20coronary%20artery%20bypass%20graft%20surgery:%20Randomised%20trial%20with%20clinical%20and%20ex-vivo%20endpoints&rft.jtitle=Anaesthesia%20critical%20care%20&%20pain%20medicine&rft.au=Lemoine,%20Sandrine&rft.date=2018-06&rft.volume=37&rft.issue=3&rft.spage=217&rft.epage=223&rft.pages=217-223&rft.issn=2352-5568&rft.eissn=2352-5568&rft_id=info:doi/10.1016/j.accpm.2017.05.009&rft_dat=%3Cproquest_cross%3E1935813333%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1935813333&rft_id=info:pmid/28870848&rft_els_id=S2352556817300267&rfr_iscdi=true |